Imatinib Terminated Phase 3 Trials for Chronic Myeloid Leukemia (CML) Treatment

IndicationsStatusPurposePhase
TerminatedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT01650805Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
NCT02174445An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two Years